On May 16, 2017, the FDA issued a black box warning for users of the diabetes medication Invokana. The alert states that based on the results of clinical trials, Invokana has been shown to vastly increase the risk of leg, foot, and toe amputations. This severe Black Box Warning comes after several prior warnings of Invokana’s amputation risks. The final results of the clinical trial confirm that Invokana may double the risk of amputation for diabetes patients. If you or a family member needed to have a leg, foot, or toe amputated while using Invokana, a personal injury lawyer may be able to help you get compensated.
Amputation Risks for Invokana Patients
Invokana is a newer medication used to treat Type II diabetes. It reduces blood glucose by increasing glucose loss in the urine. Invokana, and other drugs like it, block the normal response of glucose being reabsorbed back into the bloodstream, after being filtered through the kidneys. The active ingredient in Invokana and Invokamet is canagliflozin. Invokana contains only canagliflozin, whereas Invokament contains both canagliflozin and metformin. Both Invokana and Invokamet will contain the new Black Box Warning.
The Wieand Law Firm is investigating claims for victims who suffered injury while using the drug Invokana. If you or a loved one have had a leg, foot, or toe amputation while taking Invokana, you may be eligible for compensation. For a free legal consultation, please contact us directly at (800) 481-5206.
May 16, 2017 Black Box Warning for Invokana
The May 2017 black box warning is the strongest warning the FDA can place on a prescription medication. The black box warning for Invokana will alert patients of Invokana’s increased risk of amputation, and will be enclosed by a box with a thick, black border. The FDA recommends that healthcare practitioners consider other patient information which may add to the increased risk before prescribing Invokana. It states that conditions such as neuropathy, peripheral vascular disease, foot ulcers, and prior history of amputation may predispose patients to a need for amputation. Patients should be closely monitored, and Invokana discontinued, if complications develop.
*Disclaimer: This article is for informational purposes. It is not legal advice and should not be used as legal advice. The Wieand Law Firm, LLC is based in Philadelphia, PA, and proud to serve clients throughout Pennsylvania and New Jersey.*